Exploring Mesenchymal Stem Cells and Their Accessibility in Parkinson’s Disease Treatment
Parkinson’s disease is a progressive neurodegenerative disorder in which the patient has various motor symptoms. In the later Parkinson’s disease stages, the motor symptoms worsen, and the patient also develops nonmotor symptoms.
Parkinson’s disease is believed to be caused due to the loss of dopaminergic neurons in the substantia nigra pars compacta, which is part of the basal ganglia. The loss of neurons leads to movement slowing, as seen in Parkinson’s disease. Patients with Parkinson’s disease have characteristic symptoms such as bradykinesia (slow movements), rigidity, resting tremors, walking instability, and falls. Some non-motor symptoms include expressionless faces, sleep disturbances, depression, and cognitive decline.
Although the mechanism of Parkinson’s disease is understood to a certain extent, the current treatments only slow down the process for a bit before becoming ineffective. But with stem cells, researchers hope to change the landscape of Parkinson’s disease treatment options and hopefully provide patients with an option that not only significantly slows down disease progression but also manages to improve them.
Understanding the Financial Aspects of MSC Therapy for Parkinson’s Disease
Mesenchymal stem cell therapy is not new, but its use for Parkinson’s disease is somewhat new. It is also more costly than the normally used treatment options, oral medicines.
MSC therapy requires a lot of steps and procedures, and to ensure the procedure's safety, a lot of money is spent on the technology. MSC is not as simple as extracting and injecting cells into the patient. Some various steps and conditions need to be taken care of.
When the cells are extracted, whether from the patient or the donor, they must be extracted carefully and in a sterile environment. Then, they must be cultured with the appropriate growth factor before being injected into the patient. If, at any point, something goes wrong, the entire procedure fails. So, higher costs also ensure higher success rates.
The cost is not just for the procedure but also for evaluations before and after the procedure. So, patients must spend money to get tested to ensure they are suitable candidates. After the procedure, they must follow up with the doctor regularly to ensure that everything is going to plan. All this adds to the cost, too.
What factors determine the cost of MSC Therapy for Parkinson’s Disease?
Like any treatment option, various factors determine the cost of stem cell therapy for Parkinson’s disease. Five significant factors influence the cost of the therapy. These factors are –
The type of cells used.
The sourcing of the cells.
The number of cells acquired.
The lab in which the cells are cultured.
The quality of the cells used.
Adult stem cells, such as mesenchymal stem cells, are cheaper than embryonic stem cells, but the cost is still high. These procedures are also conducted in highly regulated and top-of-the-line labs and facilities, which further adds to the cost of the procedure.
Unlike a simple procedure for localized pain, the injection of stem cells for Parkinson’s disease is more complex, adding to the cost.
Does insurance cover MSC Therapy for Parkinson’s Disease treatment?
Currently, very few stem cell therapies are covered by insurance, and unfortunately, stem cell therapy for Parkinson’s disease is not one of them. However, you should consult various insurance providers to see what can be done.
How accessible is MSC Therapy for Parkinson’s Disease?
Since using stem cells to treat Parkinson’s disease is new, the therapy is not available as widely as some other stem cell therapies. It is also not available for patients at all Parkinson’s disease stages, as the results are better when treatment is undergone at an earlier stage.
But, there are still various places conducting this treatment that can produce promising results. You can find even more information about it by consulting experts at Swiss Medica Clinics.
What are the potential financial and logistical challenges of pursuing MSC Therapy for Parkinson’s Disease?
One of the biggest hurdles from a patient’s perspective is the cost of the therapy. It is also not a simple procedure that can be done in a single day and requires a lot of testing and follow-up visits.
Even if the cells are taken from the patient themselves, the procedures are rather complex and require a lot of technology, optimum storage, and working conditions to ensure the best results. The injection of these cells into the patient after being replicated is also a complex task and requires a lot of expertise. So, the procedure is only offered by a handful of reputable institutes.
Affordability and Accessibility of Mesenchymal Stem Cell Therapy for Parkinson’s Disease
Neurodegenerative diseases like Parkinson’s disease can be very difficult for both the patient and their family. But with advancements in science and new treatment options like stem cell therapy, there is hope for these patients.
Although the cost of stem cells to treat Parkinson’s disease are not minimal, the results can be rather promising. They can help improve the patient’s quality of life rather significantly. If you are in need of such a treatment, you can check out one of the most prominent clinics in this field, Swiss Medica in order to receive more information.
Smriti Mandhana of India (2nd L) speaks to team mates during the ICC Women's Cricket World Cup India 2025 match between India and England at Holkar Cricket Stadium on October 19, 2025 in Indore, India. (Photo by Pankaj Nangia/Getty Images)
FOUR-TIME champions England booked their ticket to the semi-finals of the Women’s World Cup after pulling off a nail-biting four-run win over hosts India in Indore on Sunday (19).
England had posted a competitive 288-8 thanks to Heather Knight’s century and held their nerve in the field to defend it, despite their bowling, usually their strong suit, being a touch off colour.
India looked to be cruising towards victory, needing just 62 runs off the last 10 overs with seven wickets in hand. But the dismissal of Smriti Mandhana turned the tide, as scoreboard pressure crept in and dot balls piled up. Soon after, Richa Ghosh and Deepti Sharma departed in quick succession, leaving the tail high and dry.
Reckless batting cost India dear. Mandhana’s downfall opened the floodgates when she danced down the track to left-arm spinner Linsey Smith but failed to clear long-off. Then, after reaching her half-century, Deepti Sharma perished trying to take on Sophie Ecclestone, a slog sweep that found deep mid-wicket to perfection. From there, the writing was on the wall.
“We probably needed 300, but we did well to pull things back and I’m very happy. Didn’t contribute much in the last couple of games, so it felt good to come up with a match-winning hundred,” said Knight, whose classy 109 off 91 balls, laced with 15 fours and a six, was the backbone of England’s innings.
England’s openers gave them a brisk start with 73 runs for the first wicket before Knight joined captain Nat Sciver-Brunt in a 113-run stand that kept the scoreboard ticking.
At one stage, England looked set to go past 300, but Knight’s run out attempting a second run triggered a slowdown, as India tightened the screws and conceded only 74 runs in the final 10 overs. Deepti Sharma was the pick of the bowlers, finishing with four wickets.
It was India’s third successive defeat leaving their next clash against New Zealand a virtual knockout. With both teams locked on four points, it’s a case of do or die to stay in the hunt for the last semi-final berth, with Australia, England and South Africa already safely through.
England, meanwhile, have been clinical, through to the semis with two games in hand. They sit second on the table with nine points, level with defending champions Australia, separated only by a whisker in Net Run Rate.
“Not sure how we lost this game. We had it in the bag. We’ve worked so hard and when the last five overs slip away from you, it’s heartbreaking. This is the third straight game we’ve lost after coming so close,” lamented India captain Harmanpreet Kaur.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.